Review efficacy data in head-to-head trials vs Rebif
The first and only therapy approved for PPMS
Safety results demonstrated in 3 pivotal Phase III studies
6-month dosing schedule

The first dose of OCREVUS is administered as two 300 mg IV infusions 2 weeks apart. Subsequent doses are administered as a single 600 mg infusion every 6 months.